265 related articles for article (PubMed ID: 27965135)
1. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody.
Yoyen-Ermis D; Ozturk K; Kursunel MA; Aydin C; Ozkazanc D; Gurbuz MU; Uner A; Tulu M; Calis S; Esendagli G
Mol Pharm; 2018 Apr; 15(4):1526-1533. PubMed ID: 29481086
[TBL] [Abstract][Full Text] [Related]
3. Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.
Daman Z; Montazeri H; Azizi M; Rezaie F; Ostad SN; Amini M; Gilani K
Pharm Res; 2015 Nov; 32(11):3756-67. PubMed ID: 26228105
[TBL] [Abstract][Full Text] [Related]
4. A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
Li PW; Luo S; Xiao LY; Tian BL; Wang L; Zhang ZR; Zeng YC
Acta Pharmacol Sin; 2019 Nov; 40(11):1448-1456. PubMed ID: 31015736
[TBL] [Abstract][Full Text] [Related]
5. Half generations magnetic PAMAM dendrimers as an effective system for targeted gemcitabine delivery.
Parsian M; Mutlu P; Yalcin S; Tezcaner A; Gunduz U
Int J Pharm; 2016 Dec; 515(1-2):104-113. PubMed ID: 27725272
[TBL] [Abstract][Full Text] [Related]
6. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.
Elechalawar CK; Hossen MN; Shankarappa P; Peer CJ; Figg WD; Robertson JD; Bhattacharya R; Mukherjee P
Int J Nanomedicine; 2020; 15():991-1003. PubMed ID: 32103952
[TBL] [Abstract][Full Text] [Related]
7. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
8. Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration.
Wu W; Driessen W; Jiang X
J Am Chem Soc; 2014 Feb; 136(8):3145-55. PubMed ID: 24506735
[TBL] [Abstract][Full Text] [Related]
9. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
10. Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines.
Yalçin S; Erkan M; Ünsoy G; Parsian M; Kleeff J; Gündüz U
Biomed Pharmacother; 2014 Jul; 68(6):737-43. PubMed ID: 25108345
[TBL] [Abstract][Full Text] [Related]
11. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer.
Fu F; Wu Y; Zhu J; Wen S; Shen M; Shi X
ACS Appl Mater Interfaces; 2014 Sep; 6(18):16416-25. PubMed ID: 25185074
[TBL] [Abstract][Full Text] [Related]
13. Transferrin Conjugated pH- and Redox-Responsive Poly(Amidoamine) Dendrimer Conjugate as an Efficient Drug Delivery Carrier for Cancer Therapy.
Hu Q; Wang Y; Xu L; Chen D; Cheng L
Int J Nanomedicine; 2020; 15():2751-2764. PubMed ID: 32368053
[TBL] [Abstract][Full Text] [Related]
14. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Lu Y; Han S; Zheng H; Ma R; Ping Y; Zou J; Tang H; Zhang Y; Xu X; Li F
Int J Nanomedicine; 2018; 13():5937-5952. PubMed ID: 30323584
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
[TBL] [Abstract][Full Text] [Related]
17. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
Kulkarni PS; Haldar MK; Nahire RR; Katti P; Ambre AH; Muhonen WW; Shabb JB; Padi SK; Singh RK; Borowicz PP; Shrivastava DK; Katti KS; Reindl K; Guo B; Mallik S
Mol Pharm; 2014 Jul; 11(7):2390-9. PubMed ID: 24827725
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
19. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S
Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652
[TBL] [Abstract][Full Text] [Related]
20. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.
Wang C; Liu B; Xu X; Zhuang B; Li H; Yin J; Cong M; Xu W; Lu A
Oncotarget; 2016 Feb; 7(7):8360-72. PubMed ID: 26840019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
